Thea Pharma
As of the edition of 20 October 2026, Thea Pharma runs 17 drugs, 17 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 17 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Cyclosporine | none listed | 3 |
| Azithromycin | none listed | 0 |
| Diclofenac | none listed | 7 |
| Timolol | none listed | 5 |
| Atropine | none listed | 12 |
| Bimatoprost | Ends 2031 (patent) | 3 |
| Latanoprost | none listed | 5 |
| Ganciclovir | none listed | 0 |
| Tetracaine | none listed | 0 |
| Articaine | none listed | 0 |
| Dorzolamide | none listed | 2 |
| Cefuroxime | none listed | 0 |
| Ketotifen | none listed | 3 |
| Tafluprost | none listed | 2 |
| Tropicamide | none listed | 1 |
| Carbomer 910 | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Thea Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.